Navigation Links
Dana-Farber and sanofi-aventis establish cancer research alliance
Date:9/23/2010

BOSTONDana-Farber Cancer Institute's Belfer Institute of Applied Cancer Science (Belfer Institute) and sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that they have entered into a collaboration and license option agreement to identify and validate novel oncology targets for further discovery and development by sanofi-aventis of novel therapeutics agents directed to such targets and related biomarkers.

Research at the Belfer Institute is focused on understanding the fundamental mechanisms of cancers, discovering and validating therapeutic targets and their clinical context in sophisticated model systems, enabling development of drug response biomarkers and supporting the discovery and development of innovative cancer treatments. Belfer Institute and sanofi-aventis' scientists will work jointly with the goal of discovering new anticancer drugs targeted at specific patient populations.

Under the terms of the agreement, Dana-Farber will receive $33 million in upfront and research funding for a minimum of three years. Dana-Farber will also be entitled to preclinical, clinical and commercial milestone payments and royalties on sales of commercial products. In return, sanofi-aventis obtains exclusive access to certain components of a transformative cancer target identification and validation platform originally developed in the laboratory of Lynda Chin, MD, the Belfer Institute's scientific director, and will also harness the strong translational capabilities of the Belfer team.

"At the Belfer Institute, our mission is to enable the discovery of novel more effective therapeutics for cancer patients. By combining our expertise in cancer genetics and translational medicine with sanofi-aventis' excellent drug discovery and development track record, this alliance has great potential to change the practice of cancer medicine," said Ronald DePinho, MD, director of Dana-Farber's Belfer Institute and professor of medicine and genetics at Harvard Medical School.

Giulio Draetta, MD, PhD, Dana-Farber's chief research business development officer and deputy director of the Belfer Institute, added "Our alliances with major pharmaceutical companies attest to our ability to be recognized as a partner in the translation of breakthrough discoveries into anti-cancer drugs. Our ability to integrate efforts at the Belfer Institute with those of other Dana-Farber's integrative research centers of excellence contributes to making our operations extremely efficient, providing a continuum of activities from discovery to clinical implementation."

"Translating research findings from academia to developing cancer drugs in the industry is a complex task that requires the collaboration of the best in the field," declared Debasish Roychowdhury, M.D., senior vice president, head of Global Oncology Division, sanofi-aventis. "We have an obligation to discover new medicines. This innovative collaboration structure with the Belfer Institute, an entirely novel organization, will strengthen sanofi-aventis Oncology's commitment to accomplish our goals."


'/>"/>

Contact: Bill Schaller
william_schaller@dfci.harvard.edu
617-632-5357
Dana-Farber Cancer Institute
Source:Eurekalert

Related biology news :

1. Dana-Farber oncologists present at ASCO GU -- predict prostate cancer survival using Source MDx test
2. McMaster, NVIDIA establish first CUDA Teaching Centre in Canada
3. Genome comparison of ants establishes new model species for molecular research
4. Stomach bacteria need vitamin to establish infection
5. New breast cancer committee to establish federal research agenda
6. 6 new research units established
7. DFG establishes 12 new research training groups
8. Covance Establishes New Discovery & Translational Services Group
9. New Tree of Life established for one of the largest groups of bacteria
10. Covance Establishes New Discovery & Translational Services Group
11. Innovalight Establishes New Record With Silicon Ink Solar Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/12/2016)... WearablesResearch.com , a brand of Troubadour Research & ... Q1 wave of its quarterly wearables survey. A particular ... a program where they would receive discounts for sharing ... "We were surprised to see that so many ... CEO of Troubadour Research, "primarily because there are segments ...
(Date:4/28/2016)... and BANGALORE, India , April ... EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... today announced a global partnership that will provide ... to use mobile banking and payment services.      ... a key innovation area for financial services, but it also ...
(Date:4/26/2016)... -- Research and Markets has announced the ...  report to their offering.  , ,     (Logo: ... forecast the global multimodal biometrics market to grow ... 2016-2020.  Multimodal biometrics is being implemented ... healthcare, BFSI, transportation, automotive, and government for controlling ...
Breaking Biology News(10 mins):
(Date:5/25/2016)... ... 25, 2016 , ... Biohaven Pharmaceutical Holding Company Ltd. (Biohaven) ... company’s orphan drug designation request covering BHV-4157 for the treatment of Spinocerebellar Ataxia ... , Spinocerebellar ataxia is a rare, debilitating neurodegenerative disorder that is estimated ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... identity. The new Media Cybernetics corporate branding reflects a results-driven revitalization for a ... image analysis. The re-branding components include a crisp, refreshed logo and a new ...
(Date:5/23/2016)... OXFORD, England , May 23, 2016 ... Wednesday, May 25 th at 10:15 a.m. ET before ... about the role genetically engineered mosquitos can play in controlling ... known carrier of the Zika virus.      (Logo: ... genetically engineered male mosquito with a self-limiting gene. Trials in ...
(Date:5/22/2016)... ... 22, 2016 , ... Doctors in Rome say micronutrients found in certain foods ... Surviving Mesothelioma has just posted an article on the new research. Click here ... Clinical Sciences and Translational Medicine evaluated more than 150 studies on polyphenols in cancer ...
Breaking Biology Technology: